Your search for apixaban returned 12 results

While the use of NSAIDs was low in the ARISTOTLE trial, NSAID users had a higher risk for bleeding than non-users.

Older patients, females, and those with comorbidities were more likely to be on multiple medications.

Researchers conducted a post hoc analysis of the ARISTOTLE trial which included patients with atrial fibrillation (AF) and a risk of stroke treated with either apixaban or warfarin for the prevention of stroke/ systemic embolism.

This is an investigational use for Eliquis.

Apixaban is a substrate of P-glycoprotein and P-glycoprotein inhibition increases drug exposure.

The researchers searched the U.S. Medicare database for NVAF patients 65 years of age and older who were newly prescribed one of the following medications: apixaban, dabigatran, rivaroxaban, or warfarin.

Reversal of anticoagulant activity of apixaban and rivaroxaban seen in older healthy participants

ANNEXA-4 is a global, single-arm, open-label clinical trial designed to evaluate andexanet alfa in patients who present with an acute major bleed while receiving apixaban, rivaroxaban, edoxaban or enoxaparin.

Novel oral anticoagulants, that do not require the laboratory monitoring associated with warfarin therapy, may alter the landscape of venous thromboembolism treatment and stroke prevention in atrial fibrillation, according to a study presented at the 52nd American Society of Hematology Meeting and Exposition.

End-stage renal disease patients on dialysis with atrial fibrillation are at high risk for thrombotic complications.